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ABSTRACT
Due to its high mortality rate and asymptomatic nature, early detection rates of 
pancreatic ductal adenocarcinoma (PDAC) remain poor.
We measured 1000 biomarker candidates in 134 clinical plasma samples by 
multiple reaction monitoring-mass spectrometry (MRM-MS). Differentially abundant 
proteins were assembled into a multimarker panel from a training set (n=684) and 
validated in independent set (n=318) from five centers. The level of panel proteins 
was also confirmed by immunoassays. The panel including leucine-rich alpha-2 
glycoprotein (LRG1), transthyretin (TTR), and CA19-9 had a sensitivity of 82.5% and 
a specificity of 92.1%. The triple-marker panel exceeded the diagnostic performance 
of CA19-9 by more than 10% (AUCCA19-9 = 0.826, AUCpanel= 0.931, P < 0.01) in all PDAC 
samples and by more than 30% (AUCCA19-9 = 0.520, AUCpanel = 0.830, P < 0.001) in 
patients with normal range of CA19-9 (<37U/mL). Further, it differentiated PDAC 
from benign pancreatic disease (AUCCA19-9 = 0.812, AUCpanel = 0.892, P < 0.01) and 
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other cancers (AUCCA19-9 = 0.796, AUCpanel = 0.899, P < 0.001).
Overall, the multimarker panel that we have developed and validated in large-
scale samples by MRM-MS and immunoassay has clinical applicability in the early 
detection of PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one 
of the most lethal gastrointestinal malignancies and the 
seventh leading cause of cancer-related deaths. Most 
pancreatic cancer (PC) patients die within 1 year after the 
initial diagnosis, and approximately 7% survives over 5 
years. However, the absence of symptoms in its initial 
stages and insufficient early detection tools lead to poor 
prognoses, and roughly 80% of the disease is unresectable 
at the time of diagnosis [1]. The close evaluation is limited 
to symptomatic or recurrent cancer patients in addition to 
lack of cost-effective, specific, and reliable screening tests 
[2]. Current diagnostic tools (e.g., imaging, biopsy) are 
likely to be expensive, time-consuming, and invasive. 
Thus, there is an unmet need for a clinical examination 
method that can discriminate malignancy from normal and 
benign states.
The identification of a biologically derived indicator 
is imperative for diseases without an appropriate treatment 
and those that experience rapid progression, leading to 
high mortality, because regular screening lowers the rates 
of late detection. Distant metastases are a contraindication 
to pancreatic resection, which is the only available 
definitive treatment [3]. The lack of accessibility to general 
screening contributes to the inability to detect PC, which 
allows the metastasis to progress and decreases survival 
rates by 50%.
The only biomarker for pancreatic cancer (PC) 
that is clinically approved by the US Food and Drug 
Administration (FDA) is serum CA-19-9. Unfortunately, 
despite its approximately 79% sensitivity and 82% 
specificity, CA-19-9 is inadequate for the early detection 
of PC in asymptomatic patients, and there is no individual 
marker that diagnoses PC with satisfactory sensitivity 
and specificity. Further, 10% to 15% of PC patients do 
not express CA19-9 due to their lack of Lewis A antigen 
[4]. Other benign diseases (e.g., obstructive jaundice) 
also increase CA19-9 levels [5]. Thus, CA19-9 merely 
indicates recurrence or functions as an ancillary modality 
to imaging devices, such as computed tomography 
(CT) and endoscopic ultrasound (EUS), in the primary 
diagnosis of PC [6].
Whereas many potential biomarkers have been 
suggested, the integration of unstructured data and 
their validation are insufficient [7]. Thus, translation of 
these compounds to the clinic has been difficult. Many 
reports have addressed the problems of invalid results 
from small sample sizes, the complexity of samples with 
various dynamic ranges of analytes, and the lack of a 
comprehensive biomarker development pipeline [8, 9]. To 
this end, we performed a large-scale multicenter validation 
of a multimarker panel by multiple reaction monitoring-
mass spectrometry (MRM-MS) and antibody-based assays 
to measure the levels of established and newly discovered 
biomarkers in PC patients and control subjects.
Usually, biomarker discovery provides myriad 
candidate proteins that need to be verified in various 
types of patient samples. Thus, MRM-MS, a highly 
selective and sensitive method of quantitating targeted 
proteins or peptides in samples, is a possible alternative 
to current PC screens [10]. Compared to typical antibody-
based clinical assays, MRM-MS is a targeted proteomics 
technology that measures at least 100 protein targets per 
sample simultaneously with precision [11]. Further, the 
existence of the antibodies is irrelevant to the quantitation 
in the validation of a large number of samples. In addition, 
MRM-MS generates consistent and reproducible datasets 
from highly complex samples between laboratories 
[12]. Thus, there is no bottleneck from the discovery to 
validation phase of most potential biomarkers in a single 
platform. We exploited the high-throughput MRM-MS 
assay to discover many potential targets and validated 
the results by a conventional antibody-based method to 
ensure that the new technology generated reliable data and 
that the identified markers could be translated easily into 
clinical practice.
To construct a better panel for screening PC, we 
measured the levels of differentially expressed proteins in 
various groups—healthy people and patients with benign 
diseases, PC, and other cancers. The resulting triple-
marker panel (LRG1, TTR, and CA19-9) was analyzed 
statistically to correlate the MRM-MS and antibody-based 
assay data with disease status and predict malignancy 
without perceptible signs. The panel performed 
significantly better than CA19-9 in different conditions. 
Thus, we report the efficacy of our panel by large-scale 
multicenter assessment of previously reported and newly 
discovered biomarkers.
RESULTS
Study population
The study participants were recruited from 5 
major medical centers in Seoul, Korea: National Cancer 
Center (NCC), Seoul National University Hospital or 
Seoul National University Hospital Healthcare System 
Gangnam Center (SNUH), Samsung Medical Center 
(SMC), Asan Medical Center (AMC), and Yonsei 
Severance Hospital (YSH). For the discovery and 
verification study, 134 plasma samples [pancreatic ductal 
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adenocarcinoma (PDAC) =50, pancreatic benign (PB) 
=34, normal control (NL) =50] were drawn between 
January 2011 and December 2013. All samples, except 
for PDAC, were acquired from our study on intraductal 
papillary mucinous neoplasms (IPMNs) [13], the purpose 
of which differed and in which the data were processed 
independently. The details on the collection of clinical 
samples are provided on Supplementary Materials. 
For the cross-platform validation studies, 1008 plasma 
samples, including those that were used in the verification 
step [PDAC =401, NL =349, other cancer (OC) =149, 
PB =109], were collected between January 2011 and 
December 2013. The normal control group comprised 
a healthy population without any malignancies or other 
serious health conditions and individuals with benign 
diseases, such as gallbladder stones and cholecystitis 
without severe inflammation. The benign pancreatic 
disease group was composed of patients with intraductal 
papillary mucinous neoplasm (IPMN). Tumor stages 
were classified per the 7th edition of AJCC [14]. The 
clinicopathological data on the study subjects are 
summarized in Supplementary Table 1  for the verification 
study and Table 1  for the validation study.
The study protocols were approved by the 
corresponding institutional review boards of all 
participating institutions (SNUH surgery H-0901-010-267, 
SNUH internal medicine H-0412-138-005 and H-0412-
138-006, SNUH HSGC H-1305-573-489 and C-1301-
095-458, YSH 4-2013-0725, NCC NCCNCS13818, SMC 
2008-07-065, AMC 2013-1061), and informed consent 
was obtained from all participants who contributed 
biospecimens.
Selection of PC-related candidate biomarkers
Candidate markers were chosen from an extensive 
database and literature search, which generated 508 
proteins that were related to PC, 22 traditional cancer 
markers, and 14 known mutated proteins [15–31]. From 
the previous microarray analysis of resected PC tissue, 
456 proteins were identified [32] (Supplementary Figure 
1 and Supplementary Materials). Of these 1000 initial 
candidates, the following criteria were used to select 
candidates (Table 2 and Supplementary Table 2): (i) 907 
proteins were filtered based on MS/MS spectra from the 
National Institute of Standards and Technology (NIST) 
MS/MS library for empirical evidence of target detection 
by mass spectrometry. (ii) Of the 907 proteins, 225 were 
actually detected in pooled plasma samples. (iii) Based 
on relative quantitation against an internal standard 
(β-galactosidase), 205 proteins and 316 peptides had AUC 
> 0.60 between the NL, PB, and PC groups. To select true 
positives, SRM collider and BLAST were performed to 
analyze unique transitions and peptides, respectively. 
(iv) Detected in biological samples by unique peptides, 
217 SIS (stable isotope-labeled standard) peptides, 
which represented 176 proteins, were synthesized and 
quantified in 134 samples. Consequently, 79 peptides 
(65 proteins) were differentially quantified. (v) Relative 
quantification of 65 proteins and 79 peptides with SIS 
peptides in triplicate analyses resulted in 54 proteins and 
68 peptides that had AUC > 0.60 between the NL and PC 
groups (Supplementary Table 3). Then, the automated 
detection of inaccurate and imprecise (AuDIT) algorithm 
was used to improve the selection of true positive targets 
by measuring the coefficient of variation (CV) in multiple 
analyses and comparing the relative intensities of analytes 
and SIS peptides to remove the possible interferences 
[33]. (vi) Finally, 68 interference-free peptides from 54 
proteins that were confidently verified were applied to 
1008 plasma samples using the MRM-MS platform. The 
overall scheme of the study is summarized in Figure 1 and 
Table 2. Collectively, the systematic selection of candidate 
targets was feasible in the plasma samples.
Confirmation of promising markers in the 
training/validation set by MRM-MS
In blood-based diagnostic methods, markers must 
perform reproducibly in a clinical environment. To 
confirm this property, we applied 3 criteria with regard 
to the stability of detection in the MRM-MS experiments 
and obtained 68 peptides, or 54 proteins (Supplementary 
Figure 2):
1. Coefficient of variance (CV) in triplicate analyses 
of the verification. Applying a cutoff of 10% CV, 26 
peptides (22 proteins) were determined to be unstable.
2. Relative peptide level (endogenous:SIS peptide 
ratio). To quantify proteins, we chose representative 
transitions that provided the highest measurement as the 
signature peptide, for which the reference range was 0.1 < 
(relative peptide level) < 10. There were 12 peptides (11 
proteins) that did not lie in this range and were excluded 
from the analysis.
3. Confounding factors, including clinical centers 
and bias across batches in the enrichment step by MRM-
MS liquid chromatography (LC). A total of 14 peptides 
(10 proteins) appeared to be affected by these factors and 
were thus excluded.
Consequently, 34 peptides (25 proteins) and CA19-
9 were selected for further analysis. Candidates were 
considered for all combinations of 1 to 5 biomarkers. We 
observed that the combinations of 2 or 3 markers resulted 
in approximately 90% specificity and 80% sensitivity, but 
the addition of more markers did not alter the performance 
significantly. Thus, we chose the classifier with 3 
biomarkers as a final candidate. The performance of each 
combination (225+1 ≈ 64,000,000 protein combinations) 
of CA19-9 and other two proteins was tested by support 
vector machine (SVM) in a training set (case n=316, 
control n=368) and a test set 1 (case n=80, control n=89) 
(Supplementary Table 4). We measured AUC values and 
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Table 1: Demographics of validation study population
Group PDAC NL OC PB
Institute NCC AMC SNUH YSH SMC SNUH SNUH YSH AMC SMC SNU
N total 128 75 50 47 101 349 149 27 47 30 5
Age 
mean 
(SD)
62.94 
(9.81)
62.2 
(10.59)
59.44 
(9.34)
64.6 
(8.56)
59.76 
(11.48)
56.94 
(8.07)
55.22 
(11.51)
59.96 
(14.15)
50.6 
(12.86)
49.99 
(15.22)
55.2 
(8.93)
BMI 
mean 
(SD)
23.32 
(2.88)
22.94 
(3.23)
22.4 
(3.32)
23.13 
(2.85)
22.52 
(2.95)
23.84 
(3.06)
23.44 
(3.41)
23.69 
(3.01)
23.26 
(4.71)
22.89 
(3.04)
23.38 
(2.08)
Sex 
ratio 
(Male 
%)
65.63 61.33 56 61.7 63.37 55.87 25.5 51.85 34.04 33.33 80
Alcohol 
ratio (# 
missing)
50.78 
(0) 52 (0)
14.58 
(2) 38.3 (0)
37.37 
(2)
79.08 
(61) 22.3 (1)
40.74 
(0)
42.55 
(0)
26.67 
(0) 20 (0)
Smoking 
ratio (# 
missing)
49.22 
(0)
38.67 
(0)
18.75 
(2)
36.17 
(0)
44.58 
(18)
41.55 
(71) 8.11 (1)
37.04 
(0)
34.04 
(0) 25 (10) 40 (0)
CA19-9 
median 312.5 51.7 82.85 59.3 363.45 7.4 9.5 7.5 7 9.33 11
CA19-9 
MAD 8032.5 415.05 358.68 328.9 1531.29 3.6 12.5 9.55 17.3 8.38 27.9
CA19-9 
missing 0 0 0 0 1 0 104 1 0 1 0
CA19-9 
censor 12 4 0 0 0 38 0 0 0 0 1
CEA 
median 5.35 2.3 1.8 2.73 2.52 1.3 1.7 2 1.1 0.79 1.7
CEA 
MAD 17.35 2.675 1.225 4.055 2.93 0.4 1.4 3 1.315 0.87 1.4
CEA 
missing 0 1 2 0 56 0 58 2 0 9 0
CEA 
censor 0 0 1 0 0 37 0 0 0 0 0
Stage of 
cancer
Breast 
(n=52)
Colon 
(n=45)
Thyroid 
(n=52)
 I 3 10 3 3 1 19 10 22
 II 27 63 45 43 50 28 12 1
 III 25 1 2 1 2 3 14 29
 IV 73 1 0 0 48 0 9 0
PC, pancreatic cancer; NL, normal; OC, other cancer (thyroid, colon, and breast); PB, pancreatic benign (pancreatitis, 
IPMN, neuroendocrine tumor, solid pseudopapillary neoplasm, mucinous cystic neoplasm, serous cystadenoma, 
pseudocyst, pancreatolithiasis); SD, standard deviation; NCC, National Cancer Center; AMC: Asan Medical Center; SNU, 
Seoul National University; YSH, Yonsei Severance Hospital; SMC, Samsung Medical Center; CA19-9, carbohydrate 
antigen 19-9; CEA, carcinoembryonic antigen; MAD, median absolute deviation.
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Figure 1: Overall scheme of the study. Through literature searches of pancreatic cancer-related journals, public databases, and 
journals on differentially expressed genes, in addition to microarray data from a previous study [32], 1000 candidates were identified. Then, 
the potential markers were detected in 134 samples, composed of 50 normal controls (25 normal and 25 benign status, such as cholecystitis), 
34 pancreatic benign disease (IPMN), and 50 PDAC groups. Targets were narrowed down by LC-MS/MS assay with stable isotope standard 
(SIS) peptide. A total of 54 proteins, or 68 peptides, were validated in a large clinical sample [n=1008; 349 normal, 109 pancreatic benign 
diseases, 149 other cancer (thyroid, breast, and colorectal cancer), and 401 pancreatic cancer] by MRM analysis and ELISA [n=1002; 
348 normal, 109 pancreatic benign diseases, 149 other cancer (thyroid, breast, and colorectal cancer), and 396 pancreatic cancer]. The 
multimarker panel was ultimately constructed by statistical analysis and supporting vector machine (SVM) method.
Table 2: Refinement of the 1000 candidates down to the 3-protein panel
Process Number of proteinsa Refinement Methodology Clinical samples
Discovery 1000 508 PC-relevant proteins Database and literature search -
456 Microarray analysis Tissue samples(n=173)
22 Traditional cancer markers -
14 Known mutated proteins -
205 Single-marker analysis MRM-MS (w/β-galactosidase)
Single-center case-
control blank plasma 
samples (n=134)
176 MRM-MS (w/SIS peptides)
Verification 65 Triplicate analysis MRM-MS (w/SIS peptides)
Validation 54 Differential single-marker candidates
MRM-MS (w/SIS 
peptides)
Multicenter case-
control blank plasma 
samples (n=1,008)
5 5 panels selected for immunoassay Multimarker analysis
3 1 panel tested Immunoassay
a the number of input proteins.
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sensitivity at a specificity of 90% (Sn|Sp=0.9) to select a 
marker or sets of markers that outperformed CA19-9 
alone. From the 5-fold cross validation of the training and 
test sets, we developed 18 panels, which resulted in at 
least a 7% higher AUC value than CA19-9 (p-value<0.05, 
DeLong’s test) [34]. Then, we selected 6 panels with 
sensitivity over 10% greater than that of CA19-9 when the 
specificity was fixed to 0.90 (p-value<0.05, McNemar’s 
test). Ultimately, 5 triple-marker panels that satisfied 
all criteria with regard to AUC values and sensitivity 
were selected (Supplementary Table 5). To examine 
reproducible performance across platforms from MRM-
MS and immunoassay, we selected a panel, comprising 
LRG1, TTR, and CA19-9, by considering their relevance 
to tumorigenesis, relatively high protein concentration 
in blood, and availability in commercial immunoassays. 
The linear response curve of these peptides is presented in 
Supplementary Figure 3. Taken together, MRM-MS assays 
and immunoassays were developed for reproducible 
markers in clinical samples.
Diagnostic performance of triple-marker panel 
in early detection
To validate the relative quantitation of the candidate 
proteins, we recorded the levels of natural proteins by 
immunoassays. Immunoassay 1 measured LRG1 by 
enzyme-linked immunosorbent assay (ELISA) and 
TTR by immunoturbidimetric assay (ITA), whereas 
Immunoassay 2 measured both LRG1 and TTR by ELISA. 
Because the results of the two assays did not significantly 
alter the outcomes, we presented the data by ELISA 
(Immunoassay 2) throughout the paper but also provided 
the Immunoassay 1 findings in Table 3.
The final panel proteins (LRG1, TTR, and CA19-
9) were tested on 1002 samples—composed of normal, 
benign, other cancers, and PDAC—which were divided 
into training (n=684) and test sets (n=318) at a 4:1 ratio 
(Supplementary Table 4). All AUC values were calculated 
by applying the classifier that was determined from the 
training set to the test sets. Two-class support vector 
machine (SVM) was performed to classify all group 
comparisons (Table 3). One group comprised PDAC 
patients, and the other groups had various compositions 
for the classification purposes. Box plots (Figure 2) and 
receiver operating characteristic curves (Figure 3) for the 
triple-marker panel and CA19-9 were generated. DeLong’s 
method and McNemar test were applied to compare two 
classifiers of the single CA19-9 and triple-marker panel 
(CA19-9+LRG1+TTR). DeLong’s method was used to 
determine whether two classifiers had the same AUC 
value. McNemar test was performed to show diagnostic 
homogeneity of the two classifiers. The sensitivity and 
specificity were obtained by applying the cut-off value 
from the training set when the specificity was set to 90.0%. 
The performance is summarized in Table 3.
The overall performance of the panel was examined 
for all PDAC samples and controls, and its ability with 
regard to early detection was evaluated in stage I/II 
PDAC compared with controls. In the first test set (Test 1, 
Supplementary Table 4) of 80 cases and 89 controls, the 
panel, as measured by MRM-MS, had an AUC value of 
0.931 (sensitivity = 82.5%), which was 11% higher than 
that of CA19-9 alone (AUC = 0.826 when sensitivity = 
72.5%) (Figure 3A). Similarly, by Immunoassay 2, the 
AUC value was 0.932 (Table 3). The levels of CA19-9 
and LRG1 increased, and TTR declined in the case group 
(Figure 2A to 2F).
To distinguish surgically operable early-stage PC, 
50 samples from only stages I and II were compared 
with 89 controls (Test 2, Supplementary Table 4). CA19-
9 had an AUC value of 0.792 (sensitivity = 64.0%). By 
MRM-MS and Immunoassay 2, the AUC values were 
0.907 and 0.914 with a sensitivity of 76.0% and 78.0%, 
respectively (Figure 3B, Table 3). The concentrations of 
CA19-9, LRG1, and TTR also changed in the early stages 
(Figure 2). These results indicate that the multimarker 
panel, rather than the individual markers, predicts the early 
stages of PDAC.
Although our panel had high sensitivity and 
specificity, its false positive detection of patients can 
lead to unnecessary examinations. Thus, we calculated 
the positive predictive value of the triple-marker panel, 
based on the actual prevalence of pancreatic cancer, which 
is 12.9 patients per 0.1 million people [35]. The positive 
predictive value (PPV) was calculated as follows:
PPV=(Sensitivity×P(D))/(Sensitivity×P(D)+(1-
Specificity)(1-P(D)))
where P(D) is 12.9/100,000, or the prevalence of 
pancreatic cancer patients in Korea. In group comparisons 
except other cancer versus PDAC, our triple-marker 
panel had improved PPV values compared with CA19-
9 (Supplementary Table 6). However, the overall PPV 
values were low due to the low prevalence of pancreatic 
cancer.
Selectivity of triple-marker panel for PC
The specificity of the panel was measured in other 
cancers, such as breast (n=52), colon (n=45), and thyroid 
(n=52) (Test 3, Supplementary Table 4). Compared with 
CA19-9 (AUC=0.796), the panel discriminated PDAC 
from other cancers better, based on a 10% increase in 
AUC values. For 80 cases versus 149 other cancers, the 
AUC values by MRM-MS and Immunoassay 2 were 0.899 
and 0.898, respectively (Figure 3C, Table 3). When the 
specificity was 83.9%, the sensitivity was 82.5%—10% 
higher than that of CA 19-9 (72.5%) (Table 3). CA19-9 
and LRG1 levels rose, whereas TTR decreased, regardless 
of platform (Figure 2A to 2F).
To select PDAC from benign pancreatic growth, 
pancreatic cancer (n=80) was distinguished from benign 
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pancreatic disease (n=21) (Test 4, Supplementary Table 
4). CA19-9 and LRG1 levels were higher compared 
with TTR, which was decreased (Figure 2A to 2F). By 
MRM-MS, CA19-9 had an AUC value of 0.812 with a 
specificity of 81.0% and sensitivity of 72.5%, whereas 
the triple-marker panel improved its AUC value to 0.892 
with a specificity of 85.7% and sensitivity of 82.5% 
(Figure 3D). Our panel had an AUC value of 0.895 
(specificity=85.7%, sensitivity=82.5%) by Immunoassay 
2 (Table 3). The results demonstrate that the triple-marker 
panel distinguishes PDAC from other cancers and benign 
diseases.
Improved performance of panel in patients with 
normal CA19-9 levels
Our panel was then tested on subjects who were 
within the normal range of CA19-9 (< 37 U/mL), because 
PC patients, primarily in the early stages, could not be 
differentiated (Figure 3E to 3H, Test 5, Supplementary 
Table 4). In the low-CA19-9 groups, the AUC value of 
CA19-9 was approximately 0.500, which demonstrated 
a lack of discriminatory power against any controls. In 
contrast, by MRM-MS and Immunoassay 2, the triple-
marker panel had an AUC value of 0.830 and 0.829, 
Table 3: Performance of triple-marker panel vs. CA19-9
Performance 
comparison CA19-9
CA19-9 + LRG1 + TTR
MRM-MS Immunoassay 1 Immunoassay 2
Control vs. PDAC AUC 0.826 0.931 (11% ↑) ** 0.940 (11% ↑) *** 0.932 (11% ↑) ***
Specificity 0.888 0.921 0.899 0.944
Sensitivity 0.725 0.825 (10% ↑) 0.825 (10% ↑) 0.825 (10% ↑)
Control vs. PDAC 
Stage I & II AUC 0.792 0.907 (11% ↑) 
** 0.915 (12% ↑) ** 0.914 (12% ↑) **
Specificity 0.888 0.921 0.899 0.944
Sensitivity 0.640 0.760 (12% ↑) 0.760 (12% ↑) 0.780 (14% ↑)
Other Cancer vs. 
PDAC AUC 0.796 0.899 (10% ↑) 
*** 0.897 (10% ↑) ** 0.898 (10% ↑) ***
Specificity 0.879 0.839 0.826 0.866
Sensitivity 0.725 0.825 (10% ↑) ** 0.825 (10% ↑) ** 0.825 (10% ↑) *
Pancreatic Benign 
vs. PDAC AUC 0.812 0.892 (8.0% ↑) 0.898 (8.6% ↑) 
* 0.895 (8.3% ↑) **
Specificity 0.810 0.857 0.810 0.857
Sensitivity 0.725 0.825 (10% ↑) 0.825 (10% ↑) * 0.825 (10% ↑)
Control vs. PDAC+ AUC 0.520 0.830 (31% ↑) *** 0.835 (32% ↑) *** 0.829 (31% ↑) ***
Specificity 0.888 0.921 0.899 0.944
Sensitivity 0.241 0.517 (28% ↑) 0.517 (28% ↑) 0.517 (28% ↑)
Control vs. PDAC 
Stage I & II+ AUC 0.567 0.818 0.832 0.834
Other Cancer vs. 
PDAC+ AUC 0.519 0.767 0.741 0.726
Pancreatic Benign 
vs. PDAC+ AUC 0.520 0.829 0.829 0.830
Performance of the panel was assessed by several assays in 5 test sets as described in Supplementary Table 4. The sensitivity 
and specificity were obtained by applying the cutoff value from the training set when the specificity was fixed to 0.9. 
DeLong’s test was used to evaluate AUC values, and two-sided p-values lower than 0.05 were considered to be significant.
* DeLong’s test, p-value < 0.05, ** DeLong’s test, p-value < 0.01, *** DeLong’s test, p-value < 0.001. + PDAC samples with 
the normal range of CA19-9 (<37U/mL).
Immunoassay 1: LRG1 measured by ELISA, TTR measured by immunoturbidimetric assay (ITA); Immunoassay 2: LRG1 
and TTR both measured by ELISA.
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respectively (Figure 3E, Table 3). The sensitivity, when 
the specificity was adjusted to roughly 90.0%, was also 
improved by 28% (sensitivity=51.7%) in control versus 
PDAC compared with the sensitivity of CA19-9, which 
was 24.1% (Table 3).
The performance of the panel in PC patients with 
CA19-9 levels within the reference range was evaluated 
under various conditions: controls vs. stage I/II PDAC, 
pancreatic benign disease vs. PDAC, and other cancers vs. 
PDAC. Each protein was measured individually, wherein 
LRG1 and TTR levels rose and decreased, respectively, 
and CA19-9 level was unchanged (Figure 2A to 2F). 
The AUC value of CA19-9 in every test setting was 
approximately 0.500. Early detection of PDAC improved, 
based on the increase in AUC value to 0.818 by MRM-MS 
and immunoassay (Figure 3F and Table 3). PDAC could 
be differentiated from other cancers, based on an AUC 
value of 0.829 by MRM-MS (Figure 3G and 3E). Benign 
and malignant pancreatic disease could be distinguished 
by the triple-marker panel, with an AUC value of 0.767, 
compared to 0.519 for CA19-9 (Figure 3H and Table 3). 
The immunoassay data correlated with these results in all 
test settings (Table 3 and Figure 2D to 2F). Collectively, 
the multimarker panel complements the performance of 
the current marker, CA19-9, in the diagnosis of pancreatic 
cancer.
DISCUSSION
In this large-scale, retrospective, and multi-center 
study, we developed a multimarker panel to diagnose the 
early stages of PDAC using conventional immunoassays 
and a high-throughput assay, followed by an advanced 
statistical machine-learning approach, to analyze the 
proteomic phenotype that is associated with genetic 
mutations or is functionally linked to pancreatic cancer. 
Figure 2: Box plots of expression of LRG1, TTR, and CA19-9 in all disease status. The levels of (A) CA19-9, (B) LRG1, 
and (C) TTR were measured in control, all stages of PDAC, stage I/II of PDAC, other cancers, pancreatic benign disease, and all stages 
of PDAC with low levels of CA19-9. LRG1 and TTR were measured by MRM-MS and are shown as a ratio of light to heavy peptides. 
CA19-9 levels were measured by immunoassay and are given in log10 (U/mL). The levels of (D) LRG1, and (E) TTR were also evaluated 
by ELISA. The concentration of (F) TTR was also measured by immunoturbidimetric assay (ITA) due to its molecular characteristics. The 
ELISA results were shown in ng/ml, whereas immunoturbidimetric assay results were given in mg/dl. CA19-9 and LRG1 tended to increase 
in PDAC, whereas TTR was decreased, regardless of immunoassay type. Even when CA19-9 levels were lower than 37 U/mL in PDAC 
patients, LRG1 and TTR levels were distinctive.
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Plasma LRG1 and TTR levels, with CA19-9, had 
greater diagnostic value for PDAC than CA19-9 alone 
(at least a 10% increase in AUC value and sensitivity at 
90% specificity for all cases). Regardless of the range 
of CA19-9 values, the multimarker panel assessed 
PDAC more accurately. In addition, as the disease 
lesion exacerbated, the levels of these markers rose or 
decreased, distinguishing early-stage cancer from benign 
diseases. These results imply that the triple-marker panel 
differentiates PC patients from inflammatory and other 
disease states in high-risk populations through regular 
health screens.
Biomarker discovery results in myriad candidate 
proteins that must be verified in various patient samples, 
but the verification of disease biomarkers delays their 
clinical translation. This study is significant, because 
we proceeded from the discovery to the validation of 
candidate markers in various platforms. Protein markers 
must be specifically overexpressed in certain cancers, 
generate stable and reproducible results, and be validated 
accurately in large cohort studies to be introduced to the 
clinic. If these requirements are met, protein markers 
have tremendous potential to become a routine clinical 
application, given that blood tests are less invasive, cost-
effective, and require small amounts of plasma. Thus, 
our goal was to perform a rapid verification of potential 
proteins and validate them by traditional antibody-based 
assays. To this end, we introduced an alternative approach, 
MRM-MS–a continuous process from the discovery to 
the validation of potential biomarkers. The lengthy lists 
of all possible targets from extensive literature searches, 
public databases, and microarrays from tissues in PC, 
benign state, and normal patients enriched our study. The 
performance of our panel was evaluated in plasma samples 
with various disease statuses. The targets were validated 
in large-scale samples using several assays to confirm the 
results. A triple-marker panel (LRG1, TTR, and CA19-
9) might lead to early diagnosis, reduce the costs of 
screening and treatment, and lengthen survival (disease-
free interval). It would also improve the quality of life of 
PC patients, because fewer invasive procedures would be 
performed and ineffective treatments would be withdrawn.
The origin and function of LRG1 and TTR are 
unclear to date. However, there has been a report that 
TTR, which is synthesized by pancreatic islets, is involved 
in pancreatic β-cell death, and insulin release [36]. TTR 
is decreased in type 1 diabetes mellitus, yet is highly 
abundant in PC juice, because the pancreatic islet is 
destroyed, allowing proteins to leak into the pancreatic 
ductal system [37, 38]. This contradictory result might 
be attributed to differences in sample types. TTR is also 
synthesized in the endocrine pancreas, liver, and choroid 
plexus of the brain, and endocrine pancreatic tumors 
contain TTR mRNA, corresponding to our previous 
microarray result [32, 39]. In addition, PDAC patients 
often experience malnutrition, lowering the levels of TTR, 
Figure 3: Receiver operating characteristic (ROC) curves for the triple-marker panel and CA19-9 in various settings. 
The general performance was examined for (A) control vs. PDAC, and early detection was evaluated for (B) control vs. stage I/II PDAC. 
For selectivity, (C) other cancers vs. PDAC and (D) pancreatic benign disease vs. PDAC were analyzed. The ROC curve of CA19-9 and 
the panel as measured by MRM-MS was also generated for patients with < 37 U/mL CA19-9 for (E) control vs. all stages of PDAC, (F) 
control vs. stage I/II PDAC, (G) other cancers vs. all stages of PDAC, and (H) pancreatic benign disease vs. all stages of PDAC. CA19-9 
had an AUC value of approximately 0.5 under all conditions; yet, the triple-marker panel had an AUC value of at least 0.767.
Oncotarget93126www.impactjournals.com/oncotarget
which is involved in energy intake, acute/chronic disease 
states, nutritional status, and inflammatory processes [40]. 
As the level of TTR declines during the progression of 
PC, TTR might originate from somewhere other than the 
cancer. However, systemic changes in cancer patients can 
alter certain proteins and represent the early physiological 
changes of cancer. LRG1 mediates angiogenesis and 
TGF-β signaling [41]. LRG1 levels are elevated in the 
blood of patients with non-small-cell lung [42], ovarian 
[43], colorectal cancer [44], and gliomas [45] through 
TGF-β signaling, which promotes endothelial cell 
proliferation and angiogenesis [46]. Elevation of LRG1 
in PC patients has been reported [47], but we improved 
the diagnostic performance of LRG1 by combining TTR 
and CA19-9. Subsequently, the triple-marker panel was 
tested in a larger cohort, including more cases that were 
in the resectable stages of pancreatic cancer and other 
cancer samples. Migration and invasion of hepatocellular 
carcinoma cells are suppressed by LRG1 [48]. A recent 
study reported that LRG1 is associated with endothelial 
dysfunction, arterial stiffness, and peripheral arterial 
disease in patients with type 2 diabetes [49]. The 
specific functions of each molecule in the panel must 
be determined, as should their molecular mechanisms 
and clinical significance. We expect that the small mass 
of an early cancer is less likely to change the molecular 
composition of peripheral blood dramatically. Rather, 
the systemic responses to abnormal changes in the organ 
might regulate the molecules that can be detected in the 
plasma by all 3 of the platforms that we used. Although 
there should be a deliberate consideration, our results 
suggest that LRG1 and TTR are highly relevant to PC.
Current studies on blood markers are examining 
the complexity of biological and individual variability. 
Moreover, PC is one of the most challenging cancers to 
evaluate, necessitating considerable research. The major 
limitation of this study was its retrospective sample 
collection, due to the retrospective exploratory nature of 
the translational research. Thus, further clinical validation 
is needed to determine the appropriateness of the panel 
in prospective screening tests and its practical feasibility. 
Focusing on patients with stage I pancreatic cancer is 
needed to form the optimal screening cohort. In this 
study, only 4 samples with stage I PC were included in 
the test set due to the low detection of stage I PC [50–52]. 
Thus, a comparison of control (normal control or benign 
pancreatic disease) and only stage I PC patients would 
not be statistically significant due to the low number of 
stage I samples. However, the main purpose of this study 
was to diagnose resectable stage I or II PC (n=50), which 
might improve overall survival through surgical resection 
and systemic therapy. The reliability of the kit should be 
tested in follow-up analyses, and its risk for generating 
false positives should be evaluated. Further, although 
this report is one of the largest validation studies on this 
subject, only one ethnic group was recruited, limiting its 
generalizability to all populations worldwide. However, 
all samples, except for the normal samples, were obtained 
from many centers, reducing institutional bias. We also 
tested the final panel in several independent cohorts. 
Trends of the marker levels in the same subject over time 
(from years before diagnosis of the cancer to the time of 
diagnosis) would be helpful in a future study.
This study is the first multicenter and large-scale 
corroboration of the clinical diagnostic value of LRG1 
and TTR among many documented candidates. This paper 
thus provides reliable evidence of the relationship between 
LRG1 and TTR with the early stages of PDAC and the 
diagnostic performance of the panel in distinguishing 
PDAC from normal, benign disease states, and the patients 
with other cancers (colorectal, thyroid, and breast cancer, 
in particular). Our findings indicate that the multimarker 
panel can guide medical decisions with regard to the 
patients in their early stages or with low CA19-9 levels. 
Furthermore, determining the function of target proteins 
and peptides in a tumor microenvironment, including 
the pathways in which they are involved, can help 
identify potential targets for treatment and increase our 
understanding of cancerous environments.
MATERIALS AND METHODS
Experimental design
To develop a multimarker panel for the early 
detection of pancreatic cancer, we generated and tested 
a panel by extensive target selection and validation in a 
large retrospective cohort from several institutions.
Over 1000 samples were allocated to the discovery/
verification (n=134) and validation sets (n=1008). A total 
of 684 plasma samples (316 PDAC, 88 PB, and 280 NL) 
constituted the training set. The verified proteins were 
rescreened in the test set of 318 plasma samples (80 
PDAC, 21 PB, 68 NL, and 149 OC). Samples from benign 
diseases, such as pancreatitis, were collected to distinguish 
cancer from benign states. Samples of other cancers 
(thyroid, breast, and colon) were included to assess cancer 
specificity. Because most pancreatic cancer patients were 
diagnosed in the metastatic or unresectable stage, we 
focused on resectable stage or early-stage disease (stage I 
and II), which might be treated successfully with surgical 
resection, followed by systemic therapy [50–52]. All 
samples were considered for biological factors, such as 
age, gender, BMI, and smoking history. In each sample 
preparation, blinding and blocked randomization were 
performed to negate any subjective bias of the sample 
groups.
All targets were measured by MRM-MS, and 
differentially abundant proteins, as determined by SVM 
learning, were assembled into a multimarker panel. The 
verification of single markers was performed in triplicate, 
whereas the validation was performed once in a large 
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clinical sample to strengthen the reliability. Two models 
(CA19-9 and multimarker panel) were trained in the 
training set, fixed, and then applied to the independent test 
set to obtain the AUC values [53]. The final targets (LRG1 
and TTR) were also measured by immunoassay. The 
performance of the panel was determined by its sensitivity 
and specificity.
Clinical plasma sample preparation for MRM-
MS analysis
High abundant plasma proteins were immune-
depleted on a multiple affinity removal system (MARS) 
column, concentrated, digested by trypsin, and desalted 
as described previously [13]. The prepared samples 
were frozen, lyophilized on speed vacuum centrifuges, 
and stored at -80°C until analysis. The samples were 
resolubilized in mobile phase A to 2 μg/μL and spiked 
with stable isotope-labeled standard (SIS) peptide, as 
needed. More details on the protocol are provided in 
Supplementary Materials.
Verification and validation of markers by 
quantitative MRM-MS assay
Individual samples were analyzed by LC-MS/MS 
on a 6490 triple quadrupole (QQQ) mass spectrometer 
(Agilent Technologies, Santa Clara, CA) that was equipped 
with ESI (iFunnel Technology source) and a capillary flow 
LC for the verification of prescreened candidate markers. 
Three transitions/peptides and a transition that showed the 
highest peak intensity were used for quantitation. Buffer 
A (0.1% formic acid/distilled water) and buffer B (0.1% 
formic acid/acetonitrile) flowed through the C18 column 
(150 mm x 0.5 mm i.d., Agilent Zorbax SB-C18, 3.5-μm 
particle size) at 20 μL/min. The peptides were eluted on a 
linear gradient of mobile phase B from 3% to 35% for 50 
min. The concentration was increased to 80% for 10 min 
and was reduced again to 5% for 10 min to equilibrate the 
column for the next run. The total LC run time was 70 
min. The ion spray capillary voltage was 2500 V, and the 
nozzle voltage was 2000 V. The drying gas temperature 
was 250°C with a flow rate of 15 L/min. The sheath gas 
temperature was 350°C with flow rate of 12 L/min. The 
nebulizer gas was set to 30 psi, the fragmentor voltage 
was 380 V, and the cell accelerator voltage was 5 V. The 
delta EMV was set to 200 V. Quadrupoles 1 and 3 were 
maintained at unit (0.7 FWHM) resolution. Peptide RT 
and optimized collision energy values were supplied to 
MassHunter (vB06.01, Agilent Technologies) to establish 
a dynamic MRM-MS scheduling method, based on input 
parameters of 1500 ± 500-ms cycle times and 4-min 
retention time windows. Dwell times varied, depending 
on the number of concurrent transitions; in all cases, they 
were at least 5 ms. Min/max dwell times were established 
by the software, and the data were analyzed using Skyline.
Validation by immunoassay
LRG1 was measured only by ELISA, and TTR 
was measured by ITA (Immunoassay 1) and ELISA 
(Immunoassay 2) due to its molecular characteristics 
and the lack of a commercial kit and references. Two 
targets, LRG1 and TTR, were tested using a commercial 
hLRG1 and prealbumin ELISA kit (IBL, Hamburg, DE, 
Germany and AssayPro, Saint Charles, MO, USA). All 
tests were performed according to the manufacturer’s 
recommendations. The concentration was obtained by 
4-parameter logistic curve-fit, multiplied by the dilution 
factors. The level of TTR was also measured using 
the COBAS© INTEGRA 800 Prealbumin kit (Roche 
Diagnostics, Basel, Switzerland).
Statistical analysis
MRM-MS peak integration was performed 
manually in Skyline. The peak area was normalized to 
that of beta-galactosidase (external standard) or the SIS 
in the same run. Statistical analyses and graphical works 
were conducted using SPSS 16.0 for Windows (SPSS 
Inc. Chicago, IL, USA), MedCalc 10.4.7.0. (MedCalc 
Software, Mariakerke, Belgium, version 10.0.1.0), R ver. 
3.2.1 (R Foundation for Statistical Computing, Vienna, 
Austria), and GraphPad Prism 5 (San Diego, CA).
Differential expression between independent 
groups was analyzed by SVM [54]. The sample groups 
were divided into training and test sets. The function of a 
diagnosis of pancreatic cancer was as follows:
f x y x x bi i
i
n
i( ) sgn( , )= < > +
=
∑α
1
where x  is the newly measured level of CA19-9, 
LRG1, and TTR; αi  is the multiplier of Lagrange; yi  is 
the identifier of normal or PC patients; xi  is the standard 
measured value; and b  is the correction value. The 
function was applied to the test set, and PC was identified 
when f x( )  was 1, whereas the normal population was 
classified when f x( )  was -1. Specificity and sensitivity 
were assessed using ROC curves, represented by 
corresponding AUC values with 95% CI. DeLong’s test 
was used to evaluate AUC values, and McNemar’s test 
was used to analyze the diagnostic performance of the 
combined panel when the specificity was 90%. Two-sided 
p-values < 0.05 were considered to be significant.
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